newsfilter
← Latest News
PR Newswire·

Eocene Announces its First European Sales and Distribution Agreement to Accelerate the Commercialization of Colospan's CG-100 Device

  • Eocene Ltd. announced that its subsidiary Colospan Ltd. signed its first European commercial distribution agreement with Hospital Line SA.
  • Hospital Line holds exclusive rights to market, sell, and distribute the CG-100 device in Greece and Cyprus.
  • Colospan plans to launch CG-100 commercially in Greece and Cyprus in parallel with its ongoing U.S. pivotal study.
  • The agreement covers exclusivity rights, mutually agreed commercial targets, and allows for the future addition of other Colospan products.
  • Hospital Line is a private distributor active in Greece and Cyprus with partnerships including Boston Scientific, LeMaitre Vascular, and Panther Healthcare.
  • CG-100 is an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas.
  • The device holds FDA Breakthrough Device Designation, CE marking under EU regulations, and approval for investigational use in the U.S. under an IDE.
  • Colospan intends to officially launch CG-100 at the upcoming 17th Hellenic-Cypriot Surgical Conference.
  • Eocene is a GI-focused medtech company headquartered in Israel that develops medical devices, therapeutics, and enabling technologies.
Company
Eocene
Keywords
Eocene